New cancer treatments are one of the most precipitous of all drugs to develop. But a renewed focus on the DNA mutations that make each cancer unique is about to expand our ability to find new treatments. Traditionally, cancer drugs have been developed by identifying compounds, more recently antibodies, that have a highly toxic effect [...]
Filed under: biomarkers, cancer, pharmaceuticals | Tagged: biomarkers, cancer, metabolic profiling, sequencing | 1 Comment »
